Nutra Pharma Corp. (NPHC)

Nutra Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.39	0.59	0.44	0.1	0.05
Revenue Growth (YoY)	-34.08%	35.73%	348.43%	88.33%	-50.29%
Cost of Revenue	0.14	0.2	0.19	0.09	0.04
Gross Profit	0.25	0.4	0.25	0.01	0.01
Selling, General & Admin	1.13	1.18	2.08	1.93	1.1
Operating Expenses	1.13	1.28	2.16	2	0.94
Operating Income	-0.88	-0.89	-1.91	-1.99	-0.92
Interest Expense	-0.32	-0.4	-0.79	-0.5	-0.34
Other Non Operating Income (Expenses)	-0.12	-0.11	11.03	-10.13	-1.1
EBT Excluding Unusual Items	-1.32	-1.4	8.33	-12.61	-2.36
Other Unusual Items	0.03	0.01	-0.15	-0.49	1.59
Pretax Income	-1.29	-1.39	8.18	-13.1	-0.77
Net Income	-1.29	-1.39	8.18	-13.1	-0.77
Net Income to Common	-1.29	-1.39	8.18	-13.1	-0.77
Shares Outstanding (Basic)	7,674	7,608	7,503	7,233	6,607
Shares Outstanding (Diluted)	7,674	7,608	19,097	7,233	6,607
Shares Change (YoY)	0.87%	-60.16%	164.03%	9.46%	40.28%
EPS (Basic)	-0.00	-0.00	0.00	-0.00	-0.00
EPS (Diluted)	-0.00	-0.00	0.00	-0.00	-0.00
Free Cash Flow	-0.42	-0.55	-0.82	-1.78	-0.88
Gross Margin	63.07%	66.64%	56.82%	8.66%	28.74%
Operating Margin	-224.00%	-149.10%	-435.21%	-2034.53%	-1782.27%
Profit Margin	-327.85%	-234.22%	1865.70%	-13399.01%	-1482.14%
Free Cash Flow Margin	-108.11%	-92.46%	-187.19%	-1824.84%	-1703.36%
EBITDA	-0.87	-0.87	-1.88	-1.98	-0.92
EBITDA Margin	-222.10%	-146.05%	-	-	-
D&A For EBITDA	0.01	0.02	0.02	0.01	0
EBIT	-0.88	-0.89	-1.91	-1.99	-0.92
EBIT Margin	-224.00%	-149.10%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.